SW
RNTX

SteelPeak Wealth’s Rein Therapeutics RNTX Stock Holding History

SteelPeak Wealth’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3K Buy
33,000
+20,000
+154% +$24.2K ﹤0.01% 630
2026
Q1 		$16.9K Buy
+13,000
New +$16.1K ﹤0.01% 572

Other funds holding RNTX

SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

SteelPeak Wealth's RNTX Position: Q2 2026 in Review

SteelPeak Wealth increased its Rein Therapeutics (RNTX) stake by 154% in Q2 2026, buying an estimated $24.2K and bringing the position to 33,000 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #630.

SteelPeak Wealth first reported a position in RNTX in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • SteelPeak Wealth held 33,000 shares of Rein Therapeutics worth $34.3K as of Q2 2026.
  • SteelPeak Wealth bought 20,000 Rein Therapeutics shares in Q2 2026, an estimated $24.2K.
  • Rein Therapeutics made up ﹤0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #630 holding.
  • SteelPeak Wealth first reported a position in Rein Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 5 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.